ClinicalTrials.gg
RecruitingNCT07212244Updated Nov 19, 2026

Analysis of Clinical Outcomes in Patients Undergoing Magnetic Resonance-Guided Focused Ultrasound for Medication-Refractory Tremor

An observational study in Essential Tremor and Essential Tremor, Movement Disorders, sponsored by Sunnybrook Health Sciences Centre. Recruiting at 1 site in Canada. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Sunnybrook Health Sciences Centre · Observational

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
240
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 26 studies in Essential Tremor with a site in Canada — 8 open to participants now, 11 under way, 1 of them phase 3. Essential Tremor · Canada.

Started
2025
with 1 other
Observational
4 of 26
2 open now
Primary completion
2031-09
later than 8 of 10 live
Registered
23rd of 26
by date
Lead sponsor
2 of 26
Sunnybrook Health Sciences Centre

Among the 26 studies in Essential Tremor with a site in Canada, this one is one of 2 that started in 2025, is one of 4 observational ones, reaches primary completion later than 8 of the 10 other live ones, and was the 23rd registered.

Essential Tremor

272 studies on the registry are indexed under Essential Tremor; 75 are open to participants now.

Browse Essential Tremor studies →

Open to participants now

8 of the 26 studies in Essential Tremor with a site in Canada are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 61 Essential Tremor studies recruiting now, 32 (52%) set no upper age limit and 5 (8%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.

This study: 22 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Essential Tremor with a site in Canada, or all of them as a file.
02

Study summary

The goal of this observational study is to evaluate the long-term efficacy and safety of MR-guided focused ultrasound (MRgFUS) thalamotomy in patients with medication-refractory essential tremor.

The main questions it aims to answer are:

  1. Does MRgFUS thalamotomy provide sustained reduction in tremor severity over 3 years?
  2. What are the long-term neurological and quality-of-life outcomes associated with this procedure?

Participants will:

  • Undergo MRgFUS thalamotomy as part of standard of care at Sunnybrook Health Sciences Centre.
  • Be followed prospectively for a minimum of 3 years with scheduled assessments including:

    1. Clinical Rating Scale for Tremor (CRST)
    2. Neurological exams and adverse event monitoring
    3. Quality of Life in Essential Tremor (QUEST) questionnaire
    4. Scale for the Assessment and Rating of Ataxia (SARA)
    5. MRI imaging and neuropsychological testing
Read the detailed description

This single-centre, prospective observational cohort study will evaluate long-term outcomes of MR-guided focused ultrasound (MRgFUS) thalamotomy for medication-refractory essential tremor at Sunnybrook Health Sciences Centre. It is anticipated that about 240 people will be recruited into this study over the next 6 years. It is expected that this study will take 6 years to complete and that results will be known in 6-7 years.

03

Conditions studied

  • Essential Tremor
  • Essential Tremor, Movement Disorders

Keywords

  • Focused Ultrasound
  • Thalamotomy
  • Hand tremor
  • MRI-guided focused ultrasound (MRgFUS)
  • Primidone
  • Propranolol
04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults aged 22 years and older with medication-refractory essential tremor and moderate-to-severe hand tremor who are scheduled to undergo MR-guided focused ultrasound (MRgFUS) thalamotomy at Sunnybrook Health Sciences Centre as part of standard of care.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 22 years or older
  2. Able and willing to give consent and to attend all visits
  3. Diagnosed with essential tremor that is to at least two tremor medications
  4. Confirmed to have moderate-to-severe hand tremor by the MRI guided Focused Ultrasound (MRgFUS) neurology team
  5. Deemed suitable surgical candidates (decision-to-treat) by the MRgFUS neurosurgical team

Exclusion criteria

Exclusion Criteria:

  1. Patients with standard to MRI such as non-MRI compatible implants or devices
  2. Patients deemed clinically unfit to undergo MRgFUS thalamotomy due to health status including (but not limited to) pregnancy, advanced kidney disease, unstable cardiac status, severe hypertension, cerebrovascular disease, brain tumour, pulmonary disorders
  3. Receiving anti-coagulants or drugs known to increase risk of hemorrhage within 2 weeks of MRgFUS procedure
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
240 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cohort 1: Magnetic Resonance-Guided Focused Ultrasound (MRgFUS) Thalamotomy

    Patients with medication-refractory essential tremor who are scheduled to undergo MRgFUS thalamotomy at Sunnybrook Health Sciences Centre as part of standard of care. Eligible participants providing informed consent will be enrolled and followed prospectively for a minimum of 3 years to evaluate long-term efficacy and safety outcomes.

06

What researchers measure

Primary outcomes

  1. Change in tremor severity measured by Clinical Rating Scale for Tremor (CRST)

    CRST is a validated scale assessing tremor severity through clinical examination and functional tasks. Tremor scores range from 0 (no tremor) to 32 for the dominant hand and 0 to 28 for the non-dominant hand, with higher scores indicating greater tremor severity. Change from baseline will be assessed. CRST measures will be videotaped following a standardized script.

    Time frame: Assessments occur at baseline; Day 1; Week 12; and at 1, 2, and 3-year follow-up visits post-treatment.

Secondary outcomes

  1. Standardized Neurological Examination and Adverse Events (AEs)

    Adverse events will be recorded and graded according to CTCAE v5.0. AEs will be recorded and categorized according to severity, and relationship to procedure.

    Time frame: Assessments occur at baseline; Day 1; Week 12; and at 1, 2, and 3-year follow-up visits post-treatment.

  2. Quality of Life in Essential Tremor (QUEST) questionnaire

    The QUEST is a self-reported, validated survey scoring the physical, psychosocial, communication, hobbies/leisure and work/finance domains of the life of a patient with Essential Tremor. Participants rate their level of agreeance with 30 statements on a 5-point scale (0 to 4), for a maximum score of 120. Higher scores reflect poorer quality of life.

    Time frame: Assessments occur at baseline; Week 12; and at 1, 2, and 3-year follow-up visits post-treatment.

  3. Scale for the Assessment and Rating of Ataxia (SARA)

    The SARA is a validated, comprehensive ataxia scale, and comprises 8 items carrying a maximum total score of 40 points. Higher scores suggest increased ataxia. The SARA will be used to compare degree of ataxia between baseline and the follow-up visits. In particular, the SARA will be used to assess changes in gait and stance associated with the procedure.

    Time frame: Assessments occur at baseline; Day 1; Week 12; and at 1, 2, and 3-year follow-up visits post-treatment.

  4. Change in MRI Measures

    MRI sequences (T1, T2\*, DTI, resting state fMRI) will be obtained to assess treatment-related changes and safety.

    Time frame: Assessments occur at baseline; Day 1; Week 12; and at 1-, 2-, and 3-year follow-up visits post-treatment.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Sep 2031, 71 months after the start.

Of 27 observational studies under Essential Tremor, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25. This study's planned 71 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2025
First posted
Oct 8, 2025
StartActual
Oct 1, 2025
Primary completionEst.
Sep 2031
CompletionEst.
Sep 2032
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date, date precision and site details
1 update, last Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Minor edits only
    + 3 other changes: verification date, date precision and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07212244
Responsible party
Dr. Nir Lipsman (Principal Investigator, Sunnybrook Health Sciences Centre) — Principal investigator
First posted
Oct 8, 2025
Start date
Oct 1, 2025
Primary completion
Sep 2031 (estimated)
Completion
Sep 2032 (estimated)
Last update
Nov 19, 2026

Study contacts

Nir Lipsman, MD, PhD, FRCSC
Contact
Nir.Lipsman@sunnybrook.ca
416-480-6954
Nadia Scantlebury, PhD
Contact
Nadia.Scantlebury@sunnybrook.ca
416- 480-6100 ext. 64390

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion